San Diego, California — According to state and local economic development sources Neurocrine Biosciences plans to invest $2,441,970.00 to build out 28,395 square feet of new space in San Diego. The company plans to occupy the new space at 12790 El Camino Real in San Diego, on or about October 1, 2020. According to the company website Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.

To learn more about Neurocrine Biosciences, visit http://www.neurocrine.com/

Company Contact:
Kevin Gorman, Chief Executive Officer
https://www.linkedin.com/in/kevin-gorman-4266076/
858-617-7600

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved